1. Guymer, Robyn H, Silva, Rufino, Ghadessi, Mercedeh, Paulding, Charles, Rittenhouse, Kay D. . ANO2 Genetic Variants and Anti-VEGF Treatment Response in Neovascular AMD: A Pharmacogenetic Substudy of VIEW 1 and VIEW 2. In Investigative ophthalmology & visual science, 65, 17. doi:10.1167/iovs.65.8.17. https://pubmed.ncbi.nlm.nih.gov/38980270/
2. Tengvall, Katarina, Huang, Jesse, Hellström, Cecilia, Olsson, Tomas, Kockum, Ingrid. 2019. Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk. In Proceedings of the National Academy of Sciences of the United States of America, 116, 16955-16960. doi:10.1073/pnas.1902623116. https://pubmed.ncbi.nlm.nih.gov/31375628/
3. Cenedese, Valentina, Mezzavilla, Massimo, Morgan, Anna, Gasparini, Paolo, Menini, Anna. 2015. Assessment of the olfactory function in Italian patients with type 3 von Willebrand disease caused by a homozygous 253 Kb deletion involving VWF and TMEM16B/ANO2. In PloS one, 10, e0116483. doi:10.1371/journal.pone.0116483. https://pubmed.ncbi.nlm.nih.gov/25635880/
4. Keckeis, Susanne, Reichhart, Nadine, Roubeix, Christophe, Strauß, Olaf. 2016. Anoctamin2 (TMEM16B) forms the Ca2+-activated Cl- channel in the retinal pigment epithelium. In Experimental eye research, 154, 139-150. doi:10.1016/j.exer.2016.12.003. https://pubmed.ncbi.nlm.nih.gov/27940219/
智鼠故事 
